We are the design-build contractor — responsible for all architectural, engineering and construction activities — for a 25,000-square-foot renovation of an existing facility to support increased production of monoclonal antibody (mAb) treatments. This project will help Elanco bring its first-in-class treatment to market globally, furthering its ability to advance animal health.
Regulated by the U.S. Department of Agriculture and European Union bodies, this project will feature significant capacity upgrades for the site. The upstream equipment includes a single-use bioreactor ballroom and harvest operations including single-use centrifugation and clarification. Downstream capabilities feature mAb previral unit operations including chromatography and viral inactivation, prior to post-viral processing and additional unit operations resulting in production of the bulk drug substance. A new pilot plant, quality control laboratory, stainless media preparation suite, buffer formulation systems and clean-in-place capabilities will also support the production needs.
To support future growth at the site, we are upgrading the central boiler, backup generator and select utility generation systems. The design and construction approach to the renovation requires strategic construction phasing to minimize shutdowns of existing operations.
Elanco’s Elwood facility plays a crucial role in manufacturing and shipping its mAb products to combat diseases like canine parvovirus (CPV), which can be deadly to unvaccinated dogs and puppies.